Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Plunges 5%; BSE HEALTHCARE Index Down 0.2%
Thu, 26 Sep 9:54

Panacea Biotech Plunges 5%; BSE HEALTHCARE Index Down 0.2%Image source: Chunumunu/www.istockphoto.com

Panacea Biotech share price has plunged 5% and is presently trading at Rs 273.1.

Meanwhile, the BSE HEALTHCARE index is at 44,093.6 (down 0.2%).

Among the top losers in the BSE HEALTHCARE index today are ALKEM LABORATORIES (down 1.2%) and LAURUS LABS (down 1.2%).

Abbott India (up 1.4%) and GRANULES INDIA (up 1.2%) are among the top gainers today.

Over the last one year, Panacea Biotech has moved up from Rs 160.5 to Rs 273.1, registering a gain of Rs 112.6 (up 70.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,800.9 to 44,093.6, registering a gain of 58.6% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 186.7%), SUVEN PHARMACEUTICALS (up 124.3%) and Glenmark Pharma (up 113.4%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 85,341.5 (up 0.2%).

The top gainers among the BSE Sensex today are Maruti Suzuki (up 2.5%) and Tata Motors (up 1.7%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 26,049.1 (up 0.2%). Maruti Suzuki and Tata Motors are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 66,023.7 to 85,341.5, registering a gain of 19,317.8 points (up 29.3%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -59.0.


Equitymaster requests your view! Post a comment on "Panacea Biotech Plunges 5%; BSE HEALTHCARE Index Down 0.2%". Click here!